SCLEROSTIN BINDING AGENT
PROBLEM TO BE SOLVED: To provide a pharmaceutical composition that contains an antibody capable of binding to Sclerostin as a protein.SOLUTION: A pharmaceutical composition contains an antibody having a light chain variable domain consisting of an amino acid sequence shown by SEQ ID No. 376 and a he...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , , , |
---|---|
Format: | Patent |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | PROBLEM TO BE SOLVED: To provide a pharmaceutical composition that contains an antibody capable of binding to Sclerostin as a protein.SOLUTION: A pharmaceutical composition contains an antibody having a light chain variable domain consisting of an amino acid sequence shown by SEQ ID No. 376 and a heavy chain variable domain consisting of an amino acid sequence shown by SEQ ID No. 378. The antibody binds to Sclerostin as SEQ ID No. 1 with a binding affinity (Kd) lower than, or equal to, 1×10M. or bonds to the sucre loss Canis familiaris var. domesticus of SEQ ID NO 1 by binding affinity (Kd) equal to 1×10M. The pharmaceutical composition can be used for treatment or prevention of a pathologic disorder developed through the medium of Sclerostin or associated with a rise in the Sclerostin level. |
---|